Two-component systems [sensor kinase/response regulator (RR)] are major tools used by microorganisms to adapt to environmental conditions. RR phosphorylation is typically required for gene activation, but few studies have addressed how and if phosphorylation affects specific steps during transcription initiation. We characterized transcription complexes made with RNA polymerase and the Bordetella pertussis RR, BvgA, in its nonphosphorylated or phosphorylated (BvgA∼P) state at P fim3 , the promoter for the virulence gene fim3 (fimbrial subunit), using gel retardation, potassium permanganate and DNase I footprinting, cleavage reactions with protein conjugated with iron bromoacetamidobenzyl-EDTA, and in vitro transcription. Previous work has shown that the level of nonphosphorylated BvgA remains high in vivo under conditions in which BvgA is phosphorylated. Our results here indicate that surprisingly both BvgA and BvgA∼P form open and initiating complexes with RNA polymerase at P fim3 . However, phosphorylation of BvgA is needed to generate the correct conformation that can transition to competent elongation. Footprints obtained with the complexes made with nonphosphorylated BvgA are atypical; while the initiating complex with BvgA synthesizes short RNA, it does not generate full-length transcripts. Extended incubation of the BvgA/RNA polymerase initiated complex in the presence of heparin generates a stable, but defective species that depends on the initial transcribed sequence of fim3. We suggest that the presence of nonphosphorylated BvgA down-regulates P fim3 activity when phosphorylated BvgA is present and may allow the bacterium to quickly adapt to the loss of inducing conditions by rapidly eliminating P fim3 activation once the signal for BvgA phosphorylation is removed.
D
espite extensive vaccination efforts and good coverage, incidence of the disease Pertussis, caused by Bordetella pertussis, has been rising since the 1980s. In recent years, coincident with a demographic shift from young children to adolescents, the rise has steepened, with more than 48,000 cases in the United States in 2012 (1) . Although the causes of this resurgence remain to be firmly established, it is clear that a better understanding of the natural history, pathogenesis, and immune response are needed to address this public health crisis. Among the virulence factors included in current acellular vaccines are pertussis toxin and the adhesins (filamentous hemagglutinin, pertactin, and fimbriae). These protein virulence factors, like almost all pertussis virulence genes, are regulated in an environmentally responsive manner by the B. pertussis BvgAS two-component system. Fimbrial expression is particularly interesting because of its additional level of control by phase and antigenic variation and its unique promoter architecture (reviewed in ref. 2) .
Fimbrial gene expression requires phosphorylation of the B. pertussis response regulator (RR) BvgA by its cognate sensor kinase (SK) BvgS. Two-component systems, such as BvgAS, are used by microorganisms to adapt their physiology and other characteristics to changing environmental conditions. Typically, a signal perceived by a SK results in autophosphorylation and subsequent transfer of the phosphate group to a conserved aspartate in the RR receiver domain. BvgS is active at 37°C and under typical culture conditions. At lower temperatures (25°C) or in the presence of nicotinic acid or magnesium sulfate (MgSO 4 ), BvgS is inactive (3) . BvgA∼P regulates transcription of up to 100 virulence genes classified as repressed, early, intermediate, and late, depending on their response to varying levels of BvgA∼P (4, 5) . These different patterns result from differences in the arrangement and affinity of BvgA∼P binding sites at the different types of promoters and, in the case of repressed genes, additional factors. Because relevant changes in virulence gene expression occur over a range of BvgA∼P levels, this system has been viewed as more like a rheostat than a simple on/off switch (ref. 5 ; reviewed in refs. 2 and 4). However, exactly how phosphorylation of BvgA modulates gene expression at specific promoters is not well understood.
Transcription initiation is the first step of protein expression regulation (reviewed in refs. 6 and 7). During this process, the enzymatic core of RNA polymerase (α 2 ββ'ω) first binds a sigma factor (σ) to form holoenzyme, RNA polymerase (RNAP). The σ factor is required to recognize specific promoter sequences, such as the -35 and -10 elements used by the primary sigmas (σ 70 of
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Escherichia coli or primary σ of B. pertussis). RNAP then binds promoter DNA and forms a closed complex (RP C ), in which the DNA is fully double-stranded. After RNAP isomerization and DNA bending and unwinding, the open complex (RP O ) is formed. RPo is usually stable and resistant to a competitor, such as heparin or DNA. Addition of NTPs generates the initiating complex RP I . Small abortive RNAs are typically synthesized and released until promoter clearance, in which the complex transitions to the elongating form as the σ factor dissociates and the nascent RNA is extruded through the RNA exit channel. As transcriptional activators, RRs might exert their influence at different steps in the initiation process, from increasing RP C and/or RP O formation, like that described for class I and class II activators (8) , to promoter clearance, as seen with the Bacillus subtilis Btr activator (9) . In some respects BvgA∼P appears to function as a class I/class II activator; its binding sites lie just upstream of or at/overlapping the -35 region of regulated promoters, and it depends on the CTD of the RNAP α subunits for function. However, unlike classic class I/II activation, in BvgA∼P activation, an αCTD is located at a BvgA∼P site but on a different face of the DNA helix (ref. 10 ; Fig. 1A ). At the promoter for fim3 (P fim3 ), the downstream BvgA∼P site actually encompasses the -35 region of the DNA. Consequently, an αCTD, a portion of the σ subunit, and a BvgA∼P dimer generate an unusual architecture in which the proteins are all located on different faces of the same sequence of DNA ( Fig. 1A; refs. 11 and 12). Furthermore, P fim3 is also regulated by phase variation by the tract of cytosines present within the -35 region of the DNA ( Fig. 1A ; ref. 13) . A length of 14 or 15 C's provides optimal activation; the presence of more or fewer C's renders P fim3 less active or inactive (11).
Here we have explored how BvgA phosphorylation influences steps in transcription initiation at the fim3 promoter. Our results indicate that although both BvgA and BvgA∼P can form stable open and initiating complexes with RNAP, these complexes appear to be structurally different and lead to two different pathways. The correct conformation, which transitions to competent elongation, is generated when BvgA is phosphorylated; in the absence of phosphorylation, a stable but inactive complex represses gene expression. Continued incubation of the initiating complex formed with nonphosphorylated BvgA results in an aberrant species that cannot be rescued under our conditions. The formation of this species depends on the sequence of the initial transcribed region of P fim3 , which we have recently shown contains a cis regulatory element, called DRE (14) . We suggest that the generation of nonproductive BvgA/RNAP/P fim3 complexes may down-regulate P fim3 activity even in the presence of BvgA∼P and may be useful to eliminate activation of P fim3 once the signal for BvgA phosphorylation is removed. Such a mechanism would allow the pathogen to rapidly deactivate fimbrial expression when conditions become inappropriate for expression.
Results
Both BvgA and BvgA∼P Form Stable Complexes with RNAP at P fim3 .
Previously, multiple transcriptional studies have characterized BvgA function by using E. coli RNAP; this polymerase is highly homologous to that of B. pertussis and has yielded in vitro results consistent with B. pertussis virulence gene expression in vivo (11, 12, 15) . However, for this work, we developed a system to purify B. pertussis RNAP core that was reconstituted with B. pertussis σ. Thus, we could directly compare results obtained with each polymerase. In addition, in all of the analyses, except for the presence or absence of acetyl phosphate, the concentrations of buffer components were kept identical when comparing BvgA vs. BvgA∼P to ensure that salt differences did not affect the results.
As expected, with either E. coli or B. pertussis polymerase, phosphorylation of BvgA is required for full-length transcription from P fim3 (Figs. 1A and 2A) or P fhaB ( Fig. 2A ; refs. 5, 11, and 16). Under our conditions, more than 90% of BvgA is phosphorylated when checked by using SDS/PAGE containing the reagent Phos-tag ( Fig. 2B; ref. 5 ).
We performed electrophoretic mobility shift assays (EMSAs) by using end-labeled DNA to ask whether phosphorylation of BvgA affects the binding of the RR, RNAP, or both to P fim3 . Neither BvgA nor BvgA∼P formed discrete complexes with P fim3 (Fig. 2C, lanes 4, 5, 9 , and 10), indicating that phosphorylation of BvgA does not simply allow this RR to bind DNA. When using B. pertussis RNAP alone, no specific complex was seen either with or without treatment with heparin, which challenges nonspecific or unstable complexes (Fig. S1, lanes 2 and 3) . Although we did observe a complex with P fim3 and E. coli RNAP (Fig. 2C, lane 2; Fig. S1, lane 15) , only a small amount of this species remained after treatment with heparin (Fig. 2C, lane 3 ; Fig. S1 , lane 16), indicating that it too was largely nonspecific and/or unstable.
In contrast, E. coli RNAP and either BvgA∼P or BvgA formed stable, heparin-resistant species with P fim3 (Fig. 2C , lanes 7 and 12, respectively). Further work (detailed below) indicates that both of these species are open complexes. B. pertussis RNAP and either BvgA or BvgA∼P formed unstable complexes with P fim3, which were not resistant to heparin challenge (Fig. S1, lanes 6  and 11) .
Thus, surprisingly, phosphorylation of BvgA did not appear to affect the formation of complexes with either polymerase, although those made with pertussis RNAP were much less stable. Based on the analyses detailed below, we named the complex obtained with E. coli RNAP and BvgA as RP O ' to distinguish it from the RP O formed with BvgA∼P.
With our template, the addition of GTP, ATP, and CTP allows the synthesis of a 13-nt transcript before encountering the need for a templated U (Fig. 1A) . In the presence of BvgA∼P and either E. coli or B. pertussis polymerase, this NTP addition resulted in a discrete species, which was heparin-resistant, con- (Table 1) . We performed these analyses by using the E. coli RNAP because B. pertussis RNAP did not yield stable open complexes. However, as discussed below, similar patterns were observed for the RP I and RP I ' species obtained with the pertussis polymerase.
We found that phosphorylation only modestly improves the binding of BvgA/RNAP to P fim3 either in the presence or absence of NTPs (K d(app) values of 0.87 μM for RP O vs. 1.8 μM for RP O ' and K d(app) values of 0.63 μM for RP I vs. 1.6 μM for RP I '). The similarity of the values of dissociation constants for BvgA or BvgA∼P also assures us that the formation of complexes with nonphosphorylated BvgA is not because of the very low level of BvgA∼P present in our purified protein.
To investigate whether phosphorylation could increase complex stability rather than affinity, we determined the half-lives (t 1/2 ) of the complexes formed with BvgA or BvgA∼P after the addition of heparin (Table 1 and (17) . In contrast, the t 1/2 of RP I (19 min) was much longer than that of RP I ' (6.0 min). However, extended incubation of RP I ' converted the complex to a slightly faster migrating species, designated RP X (Fig. 2D ). RP X is strictly specific to the nonphosphorylated form of BvgA and is not observed with BvgA∼P. Because RP X appears to be generated from RP I ' and the t 1/2 of RP X (19 min) is close to that of RP I (Table 1) , we conclude that phosphorylation does not significantly affect the stability of complexes formed at P fim3 with RNAP.
When using B. pertussis RNAP, we observed that there is actually more initiating complex produced with nonphosphorylated BvgA than with BvgA∼P (Fig. S1 , lane 7 vs. 12; Fig. 3 , lane 4 vs. 8), consistent with the idea that phosphorylation does not increase the association of the proteins with the DNA. Again, the half-lives of RP I and RP I ' were similar, ∼35 min and 30 min, respectively (Table 1) . However, most importantly, we also observed the generation of RP X with B. pertussis polymerase in the presence of the nonphosphorylated form of BvgA (Fig. 3 For DNase I footprinting, DNase I was added, and complexes were separated by EMSA before DNA isolation. Thus, we could be certain that we were only observing the footprint produced by the complex of interest. For RP O , the footprint ranged from ∼ −80 to ∼ +22 (Fig. 1B and Fig. S2B , lane 4), consistent with a typical RNAP footprint (reviewed in ref. 18 ) plus BvgA∼P binding to its sites upstream. We also observed hypersensitive sites, indicative of a distortion within the DNA duplex, at position −27 and around position +1. Distortion near these regions has also been seen with the λP R open complex (19) .
In contrast, the DNase I footprint of RP O ', obtained with nonphosphorylated BvgA, was quite different. There was less protection overall with a shorter footprint, extending from ∼ −67 to ∼+12 (Fig. 1B and Fig. S2 B and D; upstream footprint can be more easily seen in lighter exposure of Fig. S2D ). In addition, although the hypersensitive site at −27 and four of five hypersensitive sites around +1 were still present, the intensity of these cleavages differed. In particular, the cleavage at −27 was much more prominent when BvgA was not phosphorylated (Fig. S2B , lane 3 vs. lane 4).
To determine the position of BvgA∼P within RP O and BvgA within RP O ', we performed a very sensitive footprinting by using two FeBABE-conjugated mutant proteins that have already been described in the literature, BvgA T194C -FeBABE and BvgA V148C -FeBABE ( Fig. S4; ref. 10 ). Upon addition of hydrogen peroxide and ascorbic acid, FeBABE generates hydroxyl radicals that cleave both DNA and proteins within ∼18Å (20, 21) . Because T194 is located near the BvgA∼P dimer interface whereas V148 is located on the outside face of the dimer (10), the location of the generated DNA cut sites position the outside and inside edges of BvgA relative to the DNA. Because it is not possible to perform the FeBABE reaction and then isolate specific complexes by EMSA (because the generated cleavages within both DNA and protein make the complexes unstable to electrophoresis), we analyzed an aliquot of each reaction by EMSA before the addition of H 2 O 2 and ascorbic acid to confirm that the expected complexes were present (Fig. S4B) . Within RP O , the conjugated BvgA∼P proteins generated cleavages consistent with the previously described primary (−61 to −48) and secondary (promoter proximal, −39 to −26) binding regions of BvgA∼P at P fim3 (11) (Fig. 1B and Fig. S4A, lanes 3, 7, 11 , and 16). We also observed another set of cleavages upstream of the primary binding site consistent with a third binding site for a BvgA∼P dimer (−83 to −70). [The less intense cleavage sites that are approximately one helical turn away from the major sites reflect the position of the residue relative to the major and minor grooves of the DNA (22) .] Taken together with the DNase I and KMnO 4 footprints, our results indicate that RP O is an open complex that contains three dimers of BvgA∼P.
Within RP O ', nonphosphorylated BvgA was observed at the primary and secondary BvgA binding sites, but occupancy of the third, upstream site was significantly diminished (Fig. S4A , lanes 5, 9, 13, and 18). Although binding to the primary site was similar to that observed for BvgA∼P within RP O , a larger range of cleavage sites were observed in the promoter proximal site, especially when using BvgA V148C -FeBABE (Fig. S4A, compare BvgA and BvgA∼P Are Different. The results above suggested that the conformation of BvgA or its ability to form dimers might be affected by phosphorylation. Indeed, many characterized RRs exhibit changes in their dimerization profile upon phosphorylation (23) (24) (25) (26) (27) . Thus, we compared BvgA versus BvgA∼P oligomerization by using the chemical cross-linker DTSSP, which cross-links primary amines; the resulting species were separated by SDS/PAGE. When BvgA is phosphorylated, DTSSP crosslinking results in two species with apparent molecular masses of 23 kDa and 46 kDa (Fig. 4, lane 5) , suggesting that BvgA∼P exists in solution as both a monomer and a dimer. However, in the absence of phosphorylation, the primary species migrates as 23 kDa (Fig. 4, lane 2) . As expected, reversal of the cross-link by adding β-mercaptoethanol and heating to 95°C generated the 23 kDa species for either BvgA or BvgA∼P (Fig. 4, lanes 3 4) ; treated with the chemical cross-linker DTSSP (lanes 2 and 5) or treated with DTSSP followed by 5% (vol/vol) β-mercaptoethanol and then incubated 5 min at 95°C to break the cross-links (lanes 3 and 6). Products were separated by SDS/PAGE and stained with Coomassie blue. (Fig. 2C, lanes 8 and  13) . For DNase I analyses, we again isolated RP I to confirm that the footprint was only from this species. Comparison of the DNase I footprints obtained with RP O versus RP I are consistent with a dramatic change in the RNAP-DNA contacts (Fig. 1B and Fig.  S2C, lane 3 vs. 4) . The RP I footprint now extends to ∼ +37, with new hypersensitive sites appearing around -15. This pattern is typical for a productive initiating complex in which the template DNA is "scrunched" into RNAP as transcription begins (28, 29) . To confirm that RP I was actually an initiated complex, we formed the complex by using nonradioactive DNA and a radiolabeled mix of the initiating nucleotides (GTP, ATP, and [α-32 P] CTP) (Fig. 3A,  lanes 17 and 18) . This procedure demonstrated RP I contains RNA.
FeBABE footprinting was used to determine the binding of BvgA∼P within RP I . However, in this case, we were unable to isolate RP I by EMSA before the analysis. Consequently, we analyzed the complexes present in the population when the FeBABE cleavage was performed. Complexes analyzed after a 30-s treatment with heparin contained similar amounts of RP I and RP O (Fig.  S5B ), whereas after a 20-min treatment with heparin, RP I was the major species (Fig. S6B) . FeBABE footprints obtained with either population (Fig. S5A, lanes 3, 8, 13 , and 19 for the RP O /RP I mixture; Fig. S6A, lanes 3, 8, 13 , and 18 for RP I after the 20-min heparin treatment, called RP I 20' ) were consistent with the presence of BvgA∼P at the same positions observed for RP O , although the occupancy of the farthest upstream binding site was less for RP I 20' (Fig. S6 ) than for RP I (Fig. S5) . Given that the DNase I footprints of RP I extended to ∼ −80, our results suggest that RP I , like RP O , contains three BvgA∼P dimers (Fig. 1B and Fig. S2C ).
RP I ' Is an Initiated Complex That Differs from RP I . Like RP I , RP I ' could be labeled when using GTP, ATP, and [α- 32 P]CTP, indicating the presence of RNA (Fig. 3, lanes 10 and 21) . However, a comparison of the DNase I footprints for RP O ' and RP I ' (Fig.  1B and Fig. S2D, lanes 3 and 4) revealed only subtle changes in the protein-DNA contacts except for the loss of hypersensitive sites around +1 and the extension of modest protection to ∼ +32. In particular, the hypersensitive sites at −39 and −27 present in RP O ' were retained in RP I '. These results suggest that nonphosphorylated BvgA/RNA polymerase generate an atypical initiated complex at P fim3 . Within RP I ', there was little DNase I protection of the primary and secondary BvgA binding sites, suggesting lessened or different occupancy of this region than within RP O '.
For the FeBABE analyses, the population contained both RP I ' and RP O ' (Fig. S5B) . Consequently, we could only consider differences between the FeBABE footprint obtained with RP O ' (Fig. S4A, lanes 5, 9, 13, and 18 ) and the footprint with the mixture (Fig. S5A, lanes 5, 10, 16 , and 21 and summarized in Fig.  1B ). Using the RP I '/RP O ' mixture, we found a significantly wider range of cleavages within the promoter proximal (secondary) site on the nontemplate strand and less occupancy upstream than was seen with RP O ' alone, suggesting again that the overall binding of BvgA had changed. BvgA∼P. Typically, initiating complexes release abortive transcripts from 2 to ∼10 nt, until the promoter is cleared (30) (31) (32) (33) . To investigate these products from P fim3 , we used [γ- 32 P]ATP to label the 5′ end of the RNA. When using E. coli RNAP, the presence of BvgA∼P resulted in the synthesis of abortive RNAs not seen in the absence of activator (Fig. 3B, lanes 5 vs. 4 and 8  vs. 7) . In contrast, with nonphosphorylated BvgA, the level of abortive RNAs was much lower than that seen with BvgA∼P (Fig. 3B, lanes 6 and 9) and similar to the level obtained with the control using RNAP alone (Fig. 3B, lanes 4 and 7) .
When using B. pertussis RNAP and BvgA∼P, the level of products was very low compared with background, although faint bands consistent to the products observed with E. coli RNAP were just visible (Fig. 3B, lanes 2 vs. 1 ). However, with nonphosphorylated BvgA, abortive RNAs with a range of sizes were observed. In particular, there was a significant increase in the smallest products (estimated to be approximately 5 nt or less). Taken together, these results demonstrate that the pattern of abortive RNAs from P fim3 is affected both by the phosphorylation state of BvgA and whether the polymerase is from E. coli or B. pertussis.
RP X Has an Unusual Footprint but Still Contains RNAP. Extended incubation of RP I ' with heparin generated a different complex, RP X (Figs. 2D and 3A, lanes 9, 11, 20, and 22; Fig. S1, lanes 8, 21, and  29) , which migrated faster during EMSA. RPx was produced when using either E. coli or B. pertussis RNAP. DNase I protection patterns observed with the isolated RP X were subtle, and best observed by comparing traces of the DNA cut sites (Fig. 1B and  Fig. S3 ). The most striking features were a protected region from ∼+30 to +80 and hypersensitive sites at −70, −20, and −10 observed on the nontemplate strand. No strong footprints were observed on the template strand. The FeBABE analyses, performed using a mixture of RP I ' and RP X (Fig. S6B) , also revealed a new cleavage site on the template strand by using BvgA T194C -FeBABE around position −48 (Fig. S6A, lane 5 vs. Fig. S5A, lane 5) and a greater range of cleavage sites on the template strand by using BvgA V194C -FeBABE (Fig. S6A, lane 10 vs. Fig. S5A, lane 10) .
Given the unusual footprint of RP X , it was important to determine whether this species, and the other complexes formed in the presence of nonphosphorylated BvgA, contained RNAP. Consequently, we incubated complexes after treatment with heparin for various times with an antibody to the β' subunit of RNAP before EMSA. In each case, we observed a "supershift" of each complex, consistent with the presence of RNAP (Fig. 5,  lanes 3, 5, and 7) . We conclude that RNAP is present in all of the complexes, including RP X . In addition, EMSA's performed with labeled ribonucleoside triphosphates indicated that RPx contains RNA (Fig. 3A) . However, we found that the level of RNA varied from experiment to experiment, suggesting that the RNA may be disturbed during electrophoresis.
The DNA Region Downstream of Position +1 Is Required for RP X Formation. The presence of RNA within RP I ' suggested that the sequence of the transcribed region might be important for RP X formation. Therefore, we substituted the +1 G of P fim3 with an A to create P fim3 (+1A) and exchanged positions +2 to +32 with the corresponding sequence present in the B. pertussis fim2 transcript (Fig. 1A) to create P fim3 (+1A/fim2). In this second construct, the addition of ATP, CTP, and UTP results in a transcript of 14 nt (Fig. 1A) , which is similar in size to the 13-nt RNA synthesized in RP I for P fim3 (+1A). We then compared complexes made with P fim3 (+1A) and P fim3 (+1A/fim2) by EMSA. As seen in Fig. 6 , species migrating with the open and initiating complexes were observed with either template DNA in the presence of either BvgA or BvgA∼P and RP X was formed as expected with P fim3 (+1A) (lane 3). However, RP X was not observed with P fim3 (+1A/fim2).
In vitro transcription assays (Fig. S7) indicated that P fim3 , P fim3 (+1A), and P fim3 (+1A/fim2) were similarly active and dependent on phosphorylation of BvgA for the production of fulllength RNA. Thus, the sequence of the transcribed DNA and/or the RNA is required for the production of RP X , but it is not involved in BvgA∼P dependence of the P fim3 promoter.
Under inducing conditions, such as 37°C or in the absence of MgSO 4 , the sensor kinase BvgS is active, BvgA is phosphorylated, and virulence genes are expressed. Previous work has demonstrated that there are significant levels of nonphosphorylated BvgA in vivo both under inducing and noninducing conditions (5) . In contrast, BvgA∼P is not present under noninducing conditions, but it is detected within minutes upon shift to inducing conditions and is rapidly lost after a shift back (5) . Thus, the formation of RP I ' and/or RP X might afford B. pertussis with the physiological advantage of a rapid start of P fim3 gene expression when conditions are appropriate. In this scenario, nonproductive complexes at P fim3 could be poised awaiting BvgA phosphorylation. This type of behavior is observed for ArgP, which forms a nonproductive ternary complex with RNAP at the argO promoter that can respond positively or negatively depending on the changes in the intracellular ratio of arginine and lysine concentrations (34) .
To test this idea, we asked whether the addition of new BvgA∼P or Ac∼P molecules could stimulate activation from RP I ' or RP X in vitro (Fig. S8) . In this case, RP I ' and RP X were preformed by using the conditions needed to observe the complexes by EMSA. Thus, 0.5 min of heparin treatment produced RP I ', which then could be fully Fig. S8C (B. pertussis RNAP) , lanes 1-5] was added after the incubation with heparin, and we monitored the formation of labeled, full-length P fim3 RNA. As controls, the experiments were also performed by addition of BvgA or buffer in place of BvgA∼P (Fig. S8A, lanes 6-15) or Tris buffer in the place of Ac∼P (Fig. S8 B or C, lanes 6-10) , and in all transcriptions, we also included a BvgA-independent promoter, P RE# or P uvsX . Transcript production from P fim3 under these conditions was compared with positive controls in which the presence of BvgA∼P generated the competent RP I complex before the addition of Ac∼P (Fig. S8 B or C, lanes 11-20) or BvgA buffer (Fig. S8A, lanes 16-20) . Neither BvgA∼P nor Ac∼P was able to rescue transcription from RP I' or RP X . Thus, at least in vitro, RP I ' and RP X are not poised for activation. However, we cannot eliminate the possibility that the cognate kinase BvgS or other factors present in vivo might be needed for the conversion of RP I ' or RP X to active complexes.
Discussion
Transcription activators function through myriad mechanisms at various steps in transcription initiation, including RNAP recruitment, complex stabilization, isomerization, and catalysis. However, despite the identification of hundreds of two-component systems and extensive biochemical characterization of many, a full understanding of how a phosphorylated RR is able to activate transcription is still emerging.
Perhaps the best characterized example is the OmpR/PhoB family, in which phosphorylation promotes dimerization (reviewed in ref. 35) , converting a protein that binds DNA poorly into one that efficiently binds DNA. However, at the pertussis promoter P fim3 , phosphorylation of the RR BvgA is not a switch that converts a weak DNA binder into a strong one. In fact, both BvgA/RNAP and BvgA∼P/RNAP form discrete complexes at P fim3 with similar affinities and half-lives. Instead, phosphorylation changes the way BvgA binds to the DNA in the presence of RNAP, which then affects the resulting transcription. With phosphorylation, BvgA∼P facilitates formation of competent open and initiating complexes. Without phosphorylation, BvgA acts as a repressor at P fim3 , forming stable, but incompetent complexes with RNAP.
Not surprisingly, the observed footprints for RPo are as one would expect for a productive open complex (reviewed in ref. 18 ). However, in RP O ', RNAP protection of the core promoter is lessened, occupancy of the farthest upstream site is lost, and the position of BvgA within the downstream half of the promoter proximal site (positions −32 to −26; Fig. 1B) is not as discrete as that seen with BvgA∼P. The promoter proximal site within P fim3 is unique in that a BvgA∼P dimer, an αCTD, and σ region 4 occupy different faces of the same DNA helix (Fig. 1B; P-end-labeled P fim3 derivative, and either BvgA∼P (P) or BvgA (+) in the absence or presence of the indicated ribonucleoside triphosphates (A, ATP; C, CTP; G, GTP; U, UTP); complexes were treated with heparin for the indicated time before electrophoresis. P fim3 (+1A) is P fim3 in which the +1 G has been changed to an A. In P fim3 (+1A/fim2), positions +2 to +32 have also been replaced by +2 to +32 of the fim2 transcript.
dimers, we hypothesize that phosphorylation of BvgA is needed for a conformation that is optimal for the presence of the αCTD and σ region 4. This conformation, in turn, correctly positions RNAP. In addition, this conformation may also facilitate the binding of BvgA to the farthest upstream site. It appears then that although DNA is unwound in RP O ', the complex is not arranged correctly to proceed to a productive RP I . Consequently, although RP I ' is stable and contains RNA, it is not a typical "scrunched" initiating complex. For RP I ', BvgA binding at the promoter proximal site differs from that observed with the productive RP I ; it lacks significant core promoter protection although downstream DNA protection is extended. We suggest that the incorrect positioning and/or conformation of BvgA at the promoter proximal site results in an inability of RNAP to remain correctly bound to the core promoter, leading to the initiated, but nonfunctional, RP I ' (Fig. 7A) .
Why RP I ' is inhibitory is unclear. At certain promoters, the p4 regulator of Phi29 interacts with E. coli RNAP in such a way that it "overstabilizes" the initiated complex, resulting in an increase in abortive products and an inhibition of promoter clearance (36) . An increase in abortive RNAs have also been observed with inhibitory species at other promoters: H-NS repression at the rrnB P1 promoter (33) , malT transcription in the absence of the activator CRP (37) , moribund complexes at λP R (38) , and the less productive complexes made with the B. subtilis siderophore sensor BtrR in the absence of ligand (9) . Furthermore, previous work with E. coli RNAP and PrplN and PompX has found that RNA cleavage at these promoters, induced by the elongation factors GreA/GreB, is needed to overcome a promoter proximal pause (39) . Unlike these examples, we do not observe significant levels of abortives when using E. coli RNAP and nonphosphorylated BvgA, but when using B. pertussis RNAP, there is an increase in small abortive RNAs, suggesting that with this polymerase, RP I ' might also represent some type of promoter proximal pause. In either case, RP I ' transitions to the aberrant species, RP X , whose RNAP/DNA contacts differ dramatically from a typical initiating complex. Whether RP X is physiologically relevant is not yet clear. However, we have recently demonstrated that the initial transcribed sequence of fim3 contains a cis-regulatory element (DRE), whose presence significantly decreases fim3 gene expression in vivo (14) . Although we do not see such an effect of the DRE under our conditions in vitro, the finding that this sequence, which is inhibitory in vivo, also generates an inhibitory complex in vitro indicates that this portion of fim3 is highly unusual. Further analysis of the region is needed to define the mechanism of its action.
Although it is not yet known whether RP O ', RP I ', and RP X can be made in vivo, we have previously shown that the level of nonphosphorylated BvgA is high even under permissive conditions and that when cells are switched to nonpermissive conditions, the level of BvgA remains high for hours although BvgA∼P is lost within minutes (5) . Assuming that complexes with BvgA are produced in vivo as we have seen in vitro, there are two simple explanations for the adaptive value of inactive BvgA-dependent complexes. First, these species could be poised species awaiting phosphorylation. However, neither RP I ' nor RP X are rescued by the addition of Ac∼P or BvgA∼P in vitro. It is possible, however, that BvgS-mediated phosphorylation or other conditions encountered in vivo would give different results.
However, under permissive conditions, the presence of BvgA should affect the overall activity of P fim3 , because it should compete with BvgA∼P to form complexes with RNAP at P fim3 . Furthermore, BvgA should expedite fim3 deactivation once the phosphorylation signal is lost (Fig. 7B) , such as when pertussis encounters temperatures much less than 37°C as it travels from the airways of one host into the respiratory tract of another. In this way, P fim3 would not become active until the bacterium has homed to its optimal niche. From our in vitro work, it appears that the inhibitory complexes would need to disassemble to form the productive complexes with BvgA∼P. However, other conditions or factors in vivo could possibly aid in breaking up the complexes.
Interestingly, the unusual promoter architecture seen at P fim3 is not observed at all B. pertussis virulence gene promoters. Although P fim2 , like P fim3 , also contains a BvgA∼P dimer binding site coincident with the −35 region of the DNA, in other BvgAregulated promoters such as P fhaB , P ptx , and P cyaA , the promoter proximal site lies father upstream relative to the transcription start site. P fim2 and P fim3 also share the unique C-stretch within the −35 region. Random insertions and deletions within the C-stretch, which shift the BvgA sites relative to the transcription start, lead to an active or inactive promoter (11) . Thus, expression and BvgA regulation of the fim genes is tightly controlled by various mechanisms (reviewed in ref.
2). Our finding that the initial transcribed region of the fim3 sequence affects RP X formation in vitro and expression in vivo suggests that this mechanism has evolved as an adaptation and that it represents yet another level of control of fim3 expression. It is believed that cell attachment, which is mediated by Fim2, Fim3, and other bacterial adhesins, as well as detachment are integral to the pathogenesis of B. pertussis. The cell needs to attach to the host surface for infection but also needs to release from the surface to enable aerosol transmission to a new host. Expression of fim3 may need to be controlled at various levels for the best cell adaptation, especially since a new selection pressure is applied on B. pertussis with utilization of Fim3 protein in acellular vaccine. Under noninducing conditions, a basal level of transcription from the bvgA/S promoter P bvgA/S yields a low amount of BvgS and nonphosphorylated BvgA (yellow circles) (1). In the presence of a signal, BvgS phosphorylates BvgA (orange circles), which facilitates dimerization (2) and activates transcription from various early virulence gene promoters, such as P bvgA/S , P fim3 , and P fhaB (3). Increased transcription from P bvgA/S results in an increasing levels of BvgA and BvgA∼P (4). The higher levels of BvgA∼P result in the activation of late virulence gene promoters, but the continued high level of BvgA generates stable, inactive complexes at P fim3 , down-regulating its activity (5) . When the signal is removed, the level of BvgA∼P rapidly diminishes because of instability of the phospho-Asp acylphosphate bond and the BvgS phosphatase activity, leaving a large amount of nonphosphorylated BvgA (6) . Transcription from P fim3 is potentially inhibited quickly by the binding of BvgA with RNAP (7).
Experimental Procedures
DNA. Fragments containing P fim3 , P fim3 (+1A), and P fim3 (+1A/fim2), used for EMSAs and footprinting, were obtained as PCR products by using Pfu Turbo polymerase (Stratagene) and upstream and downstream PCR primers (3757up, which anneals from positions −138 to −119, and 3757dw, which anneals from positions +91 to +111 relative to the transcription start site). For production of radiolabeled DNA, the template or nontemplate primer was treated with T4 polynucleotide kinase (Optikinase; USB) in the presence of [γ-32 P]ATP. The labeled PCR product was purified as described (40) .
The wt transcription templates P fhaB (plasmid pfha; ref. 16 ), P fim3 [plasmid pP fim3-15C (12) , in which the −130 to +32 sequence surrounding the P fim3 transcription start site was cloned between the EcoRI and SalI in pSS3447; ref. 12], the extended −10 promoter P RE# (plasmid pP RE# ; refs. 11 and 41), and P uvsX (plasmid pDKT90; ref. 42) have been described. To generate the P fim3 derivative P fim3 (+1A/fim2), the sequence of pP fim3-15C from +2 to +37 was replaced with the corresponding sequence from the fim2 promoter. The +1 G to A substitutions in this plasmid and in pP fim3-15C were made by using QuikChange (Agilent) to generate P fim3 (+1A/fim2) and P fim3 (+1A), respectively. The 125-bp P fim3 fragment (positions −81 to +44) used for the in vitro transcription assays in Fig. 3B , lanes 7-9, was generated by annealing single-stranded template and nontemplate oligodeoxyribonucleotides (Eurofins MWG Operon), which had been purified by HPLC and ion exchange.
The plasmid pBpRNAP, constructed by GenScript, contains the genes for the B. pertussis Tohama I subunits of RNAP core (equivalent to E. coli rpoA, rpoB, rpoC, and rpoZ), cloned downstream of P lac between the NdeI and XbaI sites of the plasmid pQC1883 (5), a vector that is kan r and propagates in either B. pertussis or E. coli. Intervening sequences between rpoA and rpoB and between rpoC and rpoZ are the same as the corresponding sequences in the plasmid pIA1000 (generous gift of I. Artsimovitch, Department of Microbiology, Ohio State University, Columbus, OH), which expresses these genes for E. coli RNAP core. This sequence also puts an N-terminal His 6 -tag on rpoB, facilitating purification of the recombinant core.
Proteins. E. coli RNAP core was purchased from Epicentre Technologies. E. coli σ 70 (5) and His 6 -tagged B. pertussis primary σ (11) were purified as described. Wild type BvgA, BvgA C93A-C103A-V148C , and BvgA C93A-C103A-T194C were purified as described (5, 11) . When indicated, BvgA (or mutants) was phosphorylated by incubation in the presence of 20 mM acetyl phosphate (Lithium potassium acetyl phosphate; Sigma-Aldrich), 20 mM Tris-Cl (pH 8) for 30 min at room temperature. Nonphosphorylated BvgA was incubated for the same period in the presence of 20 mM Tris-Cl (pH 8) only. Levels of phosphorylated and nonphosphorylated BvgA were determined by Phos-tag SDS/PAGE as described (5) .
To purify B. pertussis RNAP core, the B. pertussis Tohama I strain BP536 (43) containing pBpRNAP was grown on Bordet Gengou agar containing 15% (vol/vol) defibrinated sheep blood, streptomycin (20 μg/mL), and kanamycin (20 μg/mL) at 37°C for 2.5 d. Cells were collected from 26 plates by scraping the agar with a cotton-tipped Q-tip and then resuspended in 2 L of PLB (44) containing streptomycin (50 μg/mL) and kanamycin (20 μg/mL) so that the starting OD 600 was ∼0.2. After incubation with shaking at 37°C for 2 h, expression of the RNAP subunits was induced by the addition of IPTG to a final concentration of 1 mM, and incubation was continued for 24 h. Cells were collected by centrifugation, yielding a 175-g pellet, and frozen at −80°C. Purification of RNAP was based on the purification of E. coli RNAP (protocol supplied by I. Artsimovitch, Ohio State University), and involved Ni 2+ affinity, heparin affinity, and MonoQ ion exchange chromatography, consecutively, using the ÄTKA system (GE Healthcare). All steps were performed on ice or in the cold. Thawed pellets (90 mg) were resuspended in 60 mL of lysis buffer [50 mM Tris-Cl (pH 6.9), 500 mM NaCl, 5% (vol/vol) glycerol] containing 2 mM benzamidine and 1 mg/mL lysozyme, homogenized in a Dounce homogenizer and left on ice for 15 min. After adding a 10% (vol/vol) solution of Tween 20 to a final concentration of 0.2%, the suspension was sonicated to 30% of the starting OD 600 and centrifuged at 27,500 × g for 30 min at 4°C. The supernatant was centrifuged again as above, and imidazole was added to the supernatant for a 10 mM final concentration. The supernatant was loaded onto a HisTrap FF 5-mL column (GE Healthcare) equilibrated with binding buffer (lysis buffer plus 10 mM imidazole), and proteins were eluted with a gradient of 10-250 mM imidazole in binding buffer (20 mL) at a flow rate of 0.5 mL/min. Fractions containing RNAP (imidazole concentrations of 150-240 mM) were pooled and dialyzed overnight into HepA buffer [50 mM Tris·HCl (pH 6.9), 5% (vol/vol) glycerol, 0.5 mM EDTA, 75 mM NaCl, 1 mM DTT] and loaded onto a HiTrap Heparin HP 5-mL column (GE Healthcare) equilibrated in HepA buffer. Proteins were eluted with a gradient of 75 mM to 1.5 M NaCl in HepA buffer (100 mL) at a flow rate of 1 mL/min. Fractions enriched for RNAP (NaCl concentrations of 0.82 M to 0.93 M) were pooled, dialyzed overnight into HepA buffer, and loaded onto an equilibrated MonoQ 5/50 GL column (GE HealthCare). Proteins were eluted with a gradient of 75 mM to 1.5 M NaCl in HepA buffer (200 mL) at a flow rate of 1 mL/min. Highly purified RNAP eluted with NaCl concentrations of 280 mM to 400 mM. Unlike in an E. coli RNAP purification, the majority of B. pertussis RNAP core did not separate from endogenous σ during the MonoQ chromatography. Consequently, fractions with and without σ were collected and then dialyzed overnight against RNAP storage buffer [50 mM Tris·HCl (pH 7.5), 50% (vol/vol) glycerol, 250 mM NaCl, 0.1 mM EDTA, 1 mM DTT]. The concentration of each B. pertussis RNAP fraction was determined after SDS/PAGE with Colloidal Coomassie blue staining (Invitrogen) by comparing the intensity of the protein bands to known amounts of E. coli RNAP. For the experiments here, we used the fraction containing core and σ, to which we added back a 2.5-fold excess of recombinant B. pertussis σ, yielding saturated RNAP holoenzyme. When using B. pertussis RNAP, the components were the same, except that the ratio of σ:core was 3:1, the glycerol concentration was 14% (vol/vol), 0.001% Triton X-100 was also present, and the NaCl concentration ranged from 45 to 80 mM. It should be noted that although a range of NaCl concentration was used overall, in any given experiment, the NaCl concentration was always identical when comparing BvgA vs. BvgA∼P. When BvgA∼P was present, reactions also included 20 mM acetyl phosphate. As indicated, NTPs were added to the reaction at a final concentration of 227 μM each. Reactions were incubated for 15 min at 37°C before the addition of heparin to a final concentration of 200 μg/mL. Samples were then loaded onto a 4% (wt/vol) polyacrylamide, nondenaturing gel already running at 100-150 V. After 3 h of electrophoresis at 400 V in 1× Tris/borate/EDTA (TBE) buffer, gels were exposed to X-ray films that were subsequently scanned on a GS800 calibrated Densitometer (Bio-Rad) and analyzed by using Quantity One software from Bio-Rad. When investigating the presence of RNA within the complex, the same conditions were used except the DNA was unlabeled and 3.75 μCi of radiolabeled [α-32 P] CTP was present in the NTPs mix.
Crosslinking of
EMSAs used to determine K d(app) and half-lives of complexes were performed similarly except that reactions contained 0.025 pmol of radiolabeled DNA, the experiments to determine half-lives were performed in the presence of 10 pmol BvgA or BvgA∼P, and in the experiments used to determine K d(app) , the concentrations for BvgA or BvgA∼P ranged from 0.025 to 1.5 μM. K d(app) was determined from the concentration of BvgA or BvgA∼P required to retard 50% of the DNA.
Supershift assays to determine whether RNAP was present in the complexes were performed as described above except that 1 μL of 1/10 dilution of anti-β' RNAP subunit (Neoclone; W0001) was added to the reaction just before loading onto gels.
In Vitro Transcriptions. Transcription reactions were performed as described (12) with minor modifications. Supercoiled template DNA containing P fim3 or its derivatives and linear pP RE# or P uvsX DNA (0.05 pmol each); 0, 2, or 5 pmol of BvgA or BvgA∼P; and 0.75 pmol reconstituted RNAP (σ:core ratio of 2.5-3:1) were mixed in 10-μL (final) reactions containing the buffer components indicated for the EMSA's described above and incubated at 37°C for 15 min before the addition of heparin (final concentration of 200 μg/mL) and NTPs (final concentration of 250 μM each ATP, GTP, and CTP and 25 μM [α- 32 P]UTP at 4.4 × 10 3 dpm/pmol). Samples were incubated for 10 min at 37°C before being placed in dry ice to stop the reaction. Formamide load solution (15 μL) was added to samples before heating 2 min at 95°C and loading 10-μL aliquots onto 4% (wt/vol) polyacrylamide, 7 M urea denaturing gels.
